{"denoms":[{"counts":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"69"},{"groupId":"BG003","value":"65"},{"groupId":"BG004","value":"385"}],"units":"Participants"}],"groups":[{"description":"The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.","id":"BG000","title":"Degarelix 80 mg / Degarelix 80 mg"},{"description":"The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.\n\nFollowing the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.","id":"BG001","title":"Degarelix 160 mg / Degarelix 160 mg"},{"description":"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.\n\nStarting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.\n\nFollowing the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.","id":"BG002","title":"Leuprolide 7.5 mg / Degarelix 80 mg"},{"description":"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.\n\nStarting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.\n\nFollowing the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.","id":"BG003","title":"Leuprolide 7.5 mg / Degarelix 160 mg"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.62","value":"70.1"},{"groupId":"BG001","spread":"8.25","value":"71.1"},{"groupId":"BG002","spread":"9.46","value":"72.4"},{"groupId":"BG003","spread":"8.24","value":"71.4"},{"groupId":"BG004","spread":"8.29","value":"71.1"}]}]}],"description":"CS21A intention-to-treat (ITT) population.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"69"},{"groupId":"BG003","value":"65"},{"groupId":"BG004","value":"385"}],"title":"Male"}]}],"description":"CS21A ITT population.","paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"48"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"26"}]}],"title":"Hungary"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"37"}]}],"title":"Czech Republic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"49"}]}],"title":"Mexico"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"18"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"31"}]}],"title":"Ukraine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"106"}]}],"title":"Romania"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"64"}]}],"title":"Russian Federation"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"}]}],"title":"Netherlands"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}]}],"title":"United Kingdom"}],"description":"CS21A ITT population.","paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.6","value":"78.4"},{"groupId":"BG001","spread":"13.4","value":"79.2"},{"groupId":"BG002","spread":"11.3","value":"78.7"},{"groupId":"BG003","spread":"12.1","value":"80.0"},{"groupId":"BG004","spread":"12.5","value":"79.0"}]}]}],"description":"CS21A ITT population.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body Weight","unitOfMeasure":"kilogram"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.92","value":"26.4"},{"groupId":"BG001","spread":"3.79","value":"26.9"},{"groupId":"BG002","spread":"3.94","value":"26.9"},{"groupId":"BG003","spread":"3.67","value":"27.1"},{"groupId":"BG004","spread":"3.84","value":"26.8"}]}]}],"description":"CS21A ITT population.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body Mass Index","unitOfMeasure":"kilogram per square meter"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"51"}]}],"title":"Gleason Score 2-4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"124"}]}],"title":"Gleason Score 5-6"},{"categories":[{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"36"},{"groupId":"BG004","value":"208"}]}],"title":"Gleason Score 7-10"}],"description":"CS21A ITT population. The Gleason Score is a system of grading the aggressiveness of the prostate cancer and how fast it is likely to grow and spread. Scale is 2-10, with low numbers being the least aggressive and 10 being the most aggressive. Two of the participants did not have a Gleason Score at Baseline.","paramType":"NUMBER","title":"Gleason Score","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"114"}]}],"title":"Localised"},{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"132"}]}],"title":"Locally advanced"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"75"}]}],"title":"Metastatic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"64"}]}],"title":"Not classifiable"}],"description":"CS21A ITT population. Prostate cancer stage was classified according to the Tumor, Nodes, and Metastatic (TNM) scale to describe the extent of cancer. Localized refers to tumors without involvement of lymph nodes or metastasis. Advanced localized can be larger tumors that may involve the lymph nodes but no metastasis. Metastatic are more advanced cancers that are spreading beyond the original tumor.","paramType":"NUMBER","title":"Stage of Prostate Cancer","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1.28","upperLimit":"10.6","value":"4.63"},{"groupId":"BG001","lowerLimit":"0.55","upperLimit":"10.6","value":"4.02"},{"groupId":"BG002","lowerLimit":"1.34","upperLimit":"12.5","value":"4.32"},{"groupId":"BG003","lowerLimit":"0.37","upperLimit":"8.00","value":"3.51"},{"groupId":"BG004","lowerLimit":"0.37","upperLimit":"12.5","value":"4.23"}]}]}],"description":"CS21A ITT population.","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Serum Testosterone Levels","unitOfMeasure":"nanograms per milliliter"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1.70","upperLimit":"3187","value":"22.2"},{"groupId":"BG001","lowerLimit":"1.50","upperLimit":"4902","value":"22.5"},{"groupId":"BG002","lowerLimit":"1.60","upperLimit":"2112","value":"25.5"},{"groupId":"BG003","lowerLimit":"1.60","upperLimit":"10952","value":"14.0"},{"groupId":"BG004","lowerLimit":"1.50","upperLimit":"10952","value":"21.0"}]}]}],"description":"CS21A ITT population.","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Serum Prostate-Specific Antigen (PSA) Levels","unitOfMeasure":"nanograms per milliliter"}],"populationDescription":"CS21A intention-to-treat (ITT) population."}